Why EVQLV? The Interesting Story Behind Our Name

Feb 19, 2020 | Blog | 1 comment

Daniel Gigante

Andrew Satz (CEO) and I had a conversation covering a question we hear quite a bit: how did we come up with the name EVQLV? It’s an interesting story that includes evolution, amino acids and startups. Enjoy!

Transcript of Conversation

Daniel: Andrew, how did you come up with the name EVQLV?

Andrew: We started working on evolutionary algorithms in 2019, and we always thought about the fact we were building things around evolution. Obviously, if you look around the internet, the word “evolution” or “evolve.com” are taken as company names. As we were developing our work, and we’re in the antibody space, and antibodies are comprised of amino acids. There are 20 common amino acids and they’re each represented by a letter of the alphabet, and the first five letters on the heavy chain of the amino acid sequence are E-V-Q-L-V.  We were like, wow, that’s very cool! It looks like the word “evolve.”

Some other things, we want to change the way people see life sciences and pharmaceuticals. So, making the “O” a “Q” was a nod to that goal. Interestingly enough, when I thought about how the logo would look, I thought we should make the line coming out of the Q a double helix…when we tried to make it, it looked really weird. EVQLV [the name] is also very startupy. You know, companies use a 3 instead of a B or a 4 instead of an A…it was really all of those things coming together and we agreed: this is an awesome name.

1 Comment

  1. Anon

    Great post, very helpful!

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

The collaboration fuses EVQLV’s expertise in AI-enabled antibody design & Manhattan BioSolutions’ expertise in antibody development in oncology

Demystifying AI In Pharma

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

Andrew Satz on the Amplifying Scientific Innovation Podcast with Dr. Sophia Ononye-Onyia

EVQLV CEO, Andrew Satz, recently joined the Amplifying Scientific Innovation podcast with Dr. Sophia Ononye-Onyia. They discussed his definition of scientific innovation, personal anecdotes of his CEO journey and EVQLV’s unique approach to scientific innovation through the acceleration of biologic therapies with the power of artificial intelligence (A.I.).

How Our Algorithm Models the Drug Discovery Process

Our CEO, Andrew Satz, recently spoked at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process.

Large Pharma’s Embrace of Artificial Intelligence

The benefits of computational drug development are well known and accepted by many in the pharmaceutical space. However, since the onset of the global pandemic, consensus went from it being an interesting concept that was almost certainly the future, to something we need implemented as soon as possible. This is one of the few silver linings of the coronavirus outbreak.

Pin It on Pinterest